| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Contineum Therapeutics, Inc.$15.19
-0.26 (-1.68%)
C 46Pipeline Score Undervalued Biotech · Commercial
Market Cap
518.18 M
EPS
-1.95
P/E Ratio
-
Value Trade
5.42 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
11.65 M
Operating CF
-16.27 M
Total Assets
261.35 M
Total Liabilities
11.31 M
Equity
250.04 M
D/E Ratio
12,345
-1.14 %
Week
4.29 %
1 Month
-12.5 %
3 Month
26.34 %
6 Month
-4.41 %
5 Year
-4.41 %
All Time
Cash Data
Cash Position
246.33 M
Monthly Burn
5.42 M
Runway
43.4 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
279.33 K
52 Week Range
3.35 - 16.33
% held by Insiders
21.8 %
% held by Institutions
73.74 %
Enterprise Value
278.80 M
Total Shares
32.74 M
Short %
8.04 %
Float Shares
26.58 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Contineum Therapeutics, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
Jun 30, 2026
●PublicationPIPE-791Presentation
Publication of discovery of PIPE-791 in Journal of Medicinal Chemistry
idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)source ↗
Drug Pipeline Intelligence
C46
Pipeline Score $981M
Pipeline ValueUndervalued
Valuation Signal4
Drugs Scored6.3x
rNPV / MCap Top 68%
Micro Cap (rank 293 of 911)
Percentile RankContineum Therapeutics, Inc. carries a moderate pipeline score (46/100), with $2.5B risk-adjusted pipeline value, led by PIPE-307 Dose A in Relapsing Remitting Multiple Sclerosis (Phase 2), across $100B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE-307 Dose A Small molecule | Relapsing Remitting Multiple Sclerosis | Phase 2 | NCT06083753 | 17% | $1.8B | COMPLETED | 182 | - | - | Aug 4, 2025 | - | Oct 23, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PIPE-791 | chronic osteoarthritis pain or chronic low back pain | Phase 1b | 2026-05-05 | demonstrating an adverse event profile generally consistent with previous PIPE-791 clinical trials; patients treated with PIPE-791 generally demonstrated improvements from baseline in pain that were numerically greater than the placebo arm Read More | CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 | |
PIPE-791 | chronic osteoarthritis pain or chronic low back pain | Phase 1b | 2026-05-05 | demonstrating an adverse event profile generally consistent with previous PIPE-791 clinical trials; patients treated with PIPE-791 generally demonstrated improvements from baseline in pain that were numerically greater than the placebo arm Read More | CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 | |
PIPE-791 | chronic osteoarthritis pain or chronic low back pain | Phase 1b | 2026-05-05 | demonstrating an adverse event profile generally consistent with previous PIPE-791 clinical trials; patients treated with PIPE-791 generally demonstrated improvements from baseline in pain that were numerically greater than the placebo arm Read More | CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CTNM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CTNM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CTNM▼ -7%on this news
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Contineum Therapeutics has published a discovery regarding its potential best-in-class LPAR1 antagonist, PIPE-791, in the Journal of Medicinal Chemistry. This publication highlights the company's ongoing research and development efforts in the biopharmaceutical sector. Further details about the implications of this discovery are not provided.
Read more →CTNMContineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Contineum Therapeutics is scheduled to present at the 2026 Goldman Sachs Global Healthcare Conference. Details regarding the presentation content or specific topics have not been disclosed in the article. The event is expected to attract significant attention from industry stakeholders.
Read more →CTNMContineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Contineum Therapeutics is scheduled to present at the 2026 RBC Capital Markets Global Healthcare Conference. The details regarding the presentation's content and significance have not been disclosed in the available information.
Read more →CTNM▼ -6.1%on this newsshared move
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Contineum Therapeutics has announced that it will present two posters at the upcoming American Thoracic Society (ATS) 2026 International Conference. The details regarding the content of the posters and their significance have not been disclosed. This event is anticipated to provide a platform for sharing research findings in the field of thoracic medicine.
Read more →CTNMContineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics has released its financial results for the first quarter of 2026. The company also reaffirmed its commitment to key clinical development milestones. Further details regarding the financial performance and specific milestones were not provided in the article.
Read more →CTNMCONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026
Contineum Therapeutics reported its first-quarter 2026 financial results, highlighting positive developments in its clinical trials. The company announced successful topline data from its chronic pain trial and initiated the PROPEL-IPF trial for idiopathic pulmonary fibrosis. With a cash runway extending into 2029, Contineum is focused on advancing its lead clinical indication while managing expenses. However, it still faced a net loss, despite improving from the previous year, and increased general and administrative costs.
Read more →CTNM▲ +7.2%on this newsshared move
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Contineum Therapeutics has granted inducement awards to two new employees as part of its 2026 Employment Inducement Equity Incentive Plan. Each award includes stock options for 51,000 shares, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to enhance its workforce as it advances its clinical programs.
Read more →CTNM▲ +6.5%on this news· ran to +20% by day 3shared move
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
Contineum Therapeutics announced positive topline results from its Phase 1b trial of PIPE-791, a selective LPA1 receptor antagonist for chronic pain. The trial demonstrated that PIPE-791 was well tolerated and showed improvements in pain intensity compared to placebo. The findings support further clinical development of PIPE-791, particularly for chronic osteoarthritis pain and chronic low back pain.
Read more →CTNM▼ -7.1%on this news
CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2025 FINANCIAL RESULTS AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES - Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of p
Contineum Therapeutics has announced its financial results for the fourth quarter of 2025, highlighting the initiation of patient dosing in the PROPEL-IPF Phase 2 trial for PIPE-791, aimed at treating idiopathic pulmonary fibrosis (IPF). The company expects topline data from another trial for PIPE-791 in chronic pain by the second quarter of 2026. Despite a supportive cash position anticipated to last through mid-2029, the company also reported an increased net loss and rising administrative expenses compared to the previous year. CEO Carmine Stengone expressed enthusiasm about the potential of their pipeline program, emphasizing the unmet needs in IPF treatment.
Read more →CTNM▲ +5.4%on this newsshared move
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Contineum Therapeutics, a clinical-stage biopharmaceutical company, will present at the 2026 Leerink Partners Global Healthcare Conference on March 11th. The presentation will highlight their innovative therapies for neuroscience, inflammation, and immunology. The company is advancing several drug candidates in clinical trials, including PIPE-791 and PIPE-307.
Read more →CTNMContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 28, 2026
Contineum Therapeutics has granted a non-qualified stock option award to a new non-executive employee as part of its 2026 Employment Inducement Equity Incentive Plan. The award consists of 23,000 shares of Class A common stock, with a vesting schedule over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and underscores the company's ongoing growth strategy.
Read more →CTNM▼ -5.3%on this news
VP, Head of Biometrics
Contineum Therapeutics is seeking a VP, Head of Biometrics to lead its Biostatistics and Data Management departments. The role involves strategic oversight of biostatistics activities, collaboration with clinical development teams, and ensuring compliance with regulatory standards. Candidates should have extensive experience in the pharmaceutical industry and a strong statistical background.
Read more →CTNMDiscovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis
The article discusses the discovery of a brain-penetrant small molecule antagonist that targets LPA1 receptors. This compound shows promise in reducing neuroinflammation and promoting remyelination in multiple sclerosis. The findings could lead to new therapeutic strategies for managing MS symptoms and improving patient outcomes.
Read more →CTNMContineum Therapeutics Announces Pricing of Initial Public Offering
Contineum Therapeutics, a clinical stage biopharmaceutical company, has announced the pricing of its initial public offering (IPO) set at $16.00 per share for 6,875,000 shares. The IPO is expected to yield gross proceeds of approximately $110 million and is anticipated to begin trading on The Nasdaq Global Select Market under the ticker CTNM on April 5, 2024. The proceeds will support Contineum's focus on developing therapies for significant clinical impairments in neuroscience, inflammation, and immunology. However, the offering is subject to customary closing conditions, highlighting some uncertainty surrounding its completion.
Read more →CTNMActive MS lesions are characterized by high LPA1 expression and PIPE-791 promotes remyelination via LPA1 inhibition in the cuprizone model
The research presented at the Gordon Research Conference 2024 highlights the role of high LPA1 expression in active multiple sclerosis (MS) lesions. It also discusses the potential of PIPE-791 in promoting remyelination through LPA1 inhibition in a cuprizone model. This study may provide new insights into MS treatment strategies.
Read more →Competitive Position
How CTNM ranks across every disease it competes inCompetitive Position is a premium feature
See how CTNM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial